Angiotech receives termination notice from Rex
In the notice, Rex has alleged that Angiotech materially breached its obligations under the agreement, and stated that the agreement will be terminated automatically on 24 April 2011.
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
Bioserve’s services include Phase I & Bioavailability/Bioequivalence studies, PK in Patient Populations, Bioanalytical Services, Statistical & IVIVC Analysis, Pharmacoscintigraphic Imaging, Clinical Trial Management and Regulatory Affairs. QPS president
Earlier, Takeda collaborated with its wholly-owned subsidiaries Takeda San Francisco, Millennium Pharmaceuticals, Takeda Bio Development Center and Chemistry, Manufacturing and Controls (CMC) Center to commercialize new drug candidate